logo
welcome
U.S. Food and Drug Administration

U.S. Food and Drug Administration

FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes

U.S. Food and Drug Administration
Summary
Nutrition label

75% Informative

Liraglutide injection is a glucagon-like peptide-1 ( GLP-1 ) receptor agonist indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes.

The FDA prioritizes assessment of generic drug applications for drugs in shortage to help improve patient access to these medications.

VR Score

68

Informative language

65

Neutral language

44

Article tone

formal

Language

English

Language complexity

80

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Source diversity

1

Affiliate links

no affiliate links